市場調查報告書

皮下自行注射市場預測:2026年

Subcutaneous Self Injection Markets to 2026

出版商 Greystone Research Associates 商品編碼 852948
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
皮下自行注射市場預測:2026年 Subcutaneous Self Injection Markets to 2026
出版日期: 2019年11月30日內容資訊: 英文
簡介

本報告提供皮下自行注射市場相關調查,產品,藥物輸送、設備策略,及產品開發要素的詳細分析,主要市場、市場動態、市場統計的評估,治療需求的促進因素分析,9個主要治療市場區隔的SC藥物的評估,市場資料、預測,及主要企業簡介等彙整。

目錄

  • 摘要整理
  • 市場機會
  • 皮下自行注射:為何成長?
  • 發展的藥物開發平台
  • 設備、封裝技術的進步
  • 患者統計的變化
  • 醫療保健經濟學
  • 需求的促進因素
  • 預填充式設備設計的革新
  • 治療目的、治療
  • 競爭情形
  • 風險要素
  • 皮下輸送設備設計要素
  • 人體工學、可用性
  • 安全功能
  • 冷凍乾燥藥物/重組
  • 高粘度藥物
  • 高容量藥物
  • 皮下輸送藥物:設備策略
  • 手持設備
  • 預填充式注射器
  • 自動注射器
  • 筆型注射器
  • 雙心腔型筆
  • 新的設備
  • 其他終端型設備
  • 無針注射器
  • 穿戴式設備
  • 貼片幫浦
  • 高容量穿戴式設備
  • 皮下自我給藥
  • 治療部門的產品分析、預測
  • 抗凝血劑
  • 抗病毒劑
  • 自體免疫疾病
  • 類風濕性關節炎
  • 乾癬性關節炎
  • 幼年型特異性關節炎
  • 僵直性脊椎炎
  • 克隆氏症
  • 自體免疫性抗發炎性SC治療藥
  • 白細胞介素受體激動劑
  • TNF抑制劑
  • 多發性硬化症
  • 糖尿病
  • 胰島素
  • 2型血糖控制
  • 造血劑
  • 荷爾蒙補充
  • 神經學
  • 骨質疏鬆症
  • 生殖健康
  • 市場要素
  • 法規的問題
  • DTC行銷
  • 市場參與企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SSJ4X9

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application. As these combination products have proliferated, so too have product strategies. Several pharma and biotech companies are embracing the combination product concept and using it to differentiate their drug offerings, while others are opting for a minimalist approach. Interferons for treating Multiple Sclerosis are primarily marketed in prefilled syringes, while human growth hormone indicated for hormone deficiency in children is supplied almost exclusively in reusable, custom-designed variable dose pen injectors. Even within a particular therapeutic drug class, strategic variations are evident.

Subcutaneous Self Injection Markets to 2026 - What You Will Learn

  • Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
  • Assesses key markets, market dynamics and market demographics
  • Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
  • Provides market data and forecasts to 2026
  • Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
  • Evaluates the impact of economic, technology, and regulatory factor

Table of Contents

Subcutaneous Self Injection Markets to 2026 - Summary of Contents

  • Executive Summary
  • The Market Opportunity
  • Subcutaneous Self-Administration - Why it's Growing
  • The Evolving Drug Pipeline
  • Device and Packaging Technology Advances
  • Shifting Patient Demographics
  • Healthcare Economics
  • Demand Drivers
  • Innovation in Prefilled Device Designs
  • Therapeutic Targets and Treatment
  • Competitive Landscape
  • Risk Factors
  • Subcutaneous Delivery Device Design Factors
  • Ergonomics and Ease of Use
  • Safety Features
  • Lyophilized Drugs/Reconstitution
  • High Viscosity Drugs
  • High Volume Drugs
  • Subcutaneously Delivered Drugs - Device Strategies
  • Handheld Devices
  • Prefilled Syringes
  • Autoinjectors
  • Pen Injectors
  • Dual Chamber Pens
  • Emerging Devices
  • Other Handheld Devices
  • Needle-free Injectors
  • Wearable Devices
  • Patch Pumps
  • Large Volume Wearable Devices
  • Subcutaneous Self-Administration
  • Therapeutic Sector Product Analysis & Forecasts
  • Anticoagulants
  • Antivirals
  • Autoimmune Diseases
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Juvenile Ideopathic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Autoimmune Anti-Inflammatory SC Therapeutics
  • Interleukin Receptor Agonists
  • TNF Inhibitors
  • Multiple Sclerosis
  • Diabetes
  • Insulin
  • Type 2 Glycemic control
  • Hematopoietics
  • Hormone Replacement
  • Neurology
  • Osteoporosis
  • Reproductive Health
  • Market Factors
  • Regulatory Issues
  • DTC Marketing
  • Market Sector Participant Profiles
Back to Top